The change comes after a twenty-year partnership with the Tantoco-led SSI Group. Marks and Spencer explained that this transition is part of a plan to support their goals for growth in the region.

Vivtex and Nimbus Therapeutics are working with big pharma to develop the next wave of oral obesity treatments.

Find latest healthcare news from every corner of the globe at Reuters.com, your online source for breaking international news ...

West Conshohocken's Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly reached blockbuster status, bringing in $958.4 ...

The two new facilities will create 300 jobs and are part of the drugmaker’s broader plan to invest $100 billion in the U.S.

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.

Mirum Pharmaceuticals reported strong FY 2025 revenues, capping an exceptional year of growth and pipeline expansion. Learn more about MIRM stock here.

Jazz Pharmaceuticals is positioned for long-term value creation, with a relief rally following Q4 2025 results and the 2026 ...

For many Filipino shoppers, the announced departure of British retailer Marks & Spencer (M&S) is more than a business ...

Moby summary of Jazz Pharmaceuticals plc's Q4 2025 earnings call ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 | When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing ...